Formycon (FYB) Stock Overview

A biotechnology company, develops biosimilar drugs in Germany and Switzerland. More details

FYB fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 60.5% below our estimate of its fair value

Earnings are forecast to grow 107.98% per year

Risk Analysis

No risks detected for FYB from our risk checks.

FYB Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW477,249 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

477,249 investors already sharing narratives

View all narratives

Formycon AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Formycon
Historical stock prices
Current Share Price	€17.85
52 Week High	€0
52 Week Low	€0
Beta	0.72
1 Month Change	1.02%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-4.11%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	FYB	CH Biotechs	CH Market
7D	2.0%	-2.1%	1.4%
1Y	n/a	17.8%	17.8%

Return vs Industry: Insufficient data to determine how FYB performed against the Swiss Biotechs industry.

Return vs Market: Insufficient data to determine how FYB performed against the Swiss Market.

Price Volatility

Is FYB's price volatile compared to industry and market?
FYB volatility
FYB Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.5%
Market Average Movement	4.1%
10% most volatile stocks in CH Market	7.9%
10% least volatile stocks in CH Market	2.2%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine FYB's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	203	Stefan Glombitza	www.formycon.com

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names.

Formycon AG Fundamentals Summary

How do Formycon's earnings and revenue compare to its market cap?
FYB fundamental statistics
Market cap	CHF 316.08m
Earnings (TTM)	-CHF 53.05m
Revenue (TTM)	CHF 48.75m

6.5x

P/S Ratio

-6.0x

P/E Ratio

Is FYB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FYB income statement (TTM)
Revenue	€52.28m
Cost of Revenue	€42.00m
Gross Profit	€10.28m
Other Expenses	€67.17m
Earnings	-€56.90m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Aug 12, 2026

Earnings per share (EPS)	-3.22
Gross Margin	19.66%
Net Profit Margin	-108.84%
Debt/Equity Ratio	0%

How did FYB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/31 00:23
End of Day Share Price	2026/07/31 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Formycon AG is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Gerhard Orgonas	Berenberg
Benjamin Thielmann	Berenberg
Simon Scholes	First Berlin Equity Research GmbH